Covaxin, manufactured by the Hyderabad-based pharma major Bharat Biotech, will be available in Bahrain for people aged 18 years and above after the approval.
"We are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners- Ocugen," tweeted Dr Raches Ella, Bharat Biotech's clinical lead for Covid-19 vaccines.
The Australian regulatory authority for therapeutic goods ‘Therapeutic Goods Administration’ (TGA), Department of Health released a notice recognising Covaxin for the purpose of establishing a traveller’s vaccination status.
United Nations/Geneva: A decision on Bharat Biotech’s submission seeking emergency use listing (EUL) for its Covaxin COVID-19 vaccine will be made in October, the World Health Organisation has said. The status of assessment for Covaxin is “ongoing”. Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The latest ‘Status of […]
Several research activities are being carried out to study Variants of Concern and assess their suitability for follow-up booster doses, the company said here on Tuesday.
In the EOI, the Directorate General of Health Services (DGHS) stated that the offered vaccine must be duly approved by a competent authority of the government of India.